Odonate Therapeutics Inc
OTC:ODTC
Income Statement
Earnings Waterfall
Odonate Therapeutics Inc
Income Statement
Odonate Therapeutics Inc
| Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(3)
|
(6)
|
(10)
|
(19)
|
(33)
|
(47)
|
(63)
|
(77)
|
(91)
|
(103)
|
(113)
|
(116)
|
(115)
|
(117)
|
(121)
|
(124)
|
(127)
|
(125)
|
(107)
|
(91)
|
|
| Selling, General & Administrative |
(0)
|
(1)
|
(1)
|
(2)
|
(5)
|
(7)
|
(9)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(10)
|
(10)
|
(11)
|
(19)
|
|
| Research & Development |
(3)
|
(5)
|
(8)
|
(17)
|
(28)
|
(40)
|
(54)
|
(66)
|
(80)
|
(92)
|
(102)
|
(105)
|
(104)
|
(105)
|
(110)
|
(113)
|
(117)
|
(115)
|
(97)
|
(71)
|
|
| Operating Income |
(3)
N/A
|
(6)
-87%
|
(10)
-65%
|
(19)
-99%
|
(33)
-73%
|
(47)
-43%
|
(63)
-34%
|
(77)
-23%
|
(91)
-18%
|
(103)
-14%
|
(113)
-9%
|
(116)
-3%
|
(115)
+1%
|
(117)
-1%
|
(121)
-4%
|
(124)
-2%
|
(127)
-3%
|
(125)
+2%
|
(107)
+14%
|
(91)
+15%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(5)
|
(12)
|
(12)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
1
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(3)
N/A
|
(6)
-87%
|
(10)
-65%
|
(19)
-99%
|
(33)
-73%
|
(47)
-43%
|
(62)
-33%
|
(76)
-22%
|
(89)
-17%
|
(101)
-13%
|
(110)
-9%
|
(113)
-2%
|
(112)
+1%
|
(113)
-1%
|
(118)
-4%
|
(122)
-3%
|
(126)
-4%
|
(130)
-3%
|
(119)
+9%
|
(102)
+14%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(3)
|
(6)
|
(10)
|
(19)
|
(33)
|
(47)
|
(62)
|
(76)
|
(89)
|
(101)
|
(110)
|
(113)
|
(112)
|
(113)
|
(118)
|
(122)
|
(126)
|
(130)
|
(119)
|
(102)
|
|
| Net Income (Common) |
(3)
N/A
|
(6)
-87%
|
(10)
-65%
|
(19)
-99%
|
(33)
-73%
|
(47)
-43%
|
(62)
-33%
|
(76)
-22%
|
(89)
-17%
|
(101)
-13%
|
(110)
-9%
|
(113)
-2%
|
(112)
+1%
|
(113)
-1%
|
(118)
-4%
|
(122)
-3%
|
(126)
-4%
|
(130)
-3%
|
(119)
+9%
|
(102)
+14%
|
|
| EPS (Diluted) |
-4.65
N/A
|
-8.58
-85%
|
-14.19
-65%
|
-28.17
-99%
|
-48.7
-73%
|
-77.03
-58%
|
-102.26
-33%
|
-124.22
-21%
|
-145.46
-17%
|
-163.23
-12%
|
-176.81
-8%
|
-148.98
+16%
|
-161.91
-9%
|
-148.1
+9%
|
-153.92
-4%
|
-148.57
+3%
|
-153.79
-4%
|
-138.98
+10%
|
-125.04
+10%
|
-107.65
+14%
|
|